400 - The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma

Autor: Diallo, B., Massonnet, G., El-Botty, R., Raymondie, C., Howes, C., Wilson, J., Smith, A., Roman-Roman, S., Smith, P., Davies, E., Decaudin, D., Némati, F.

Publikováno v: In European Journal of Cancer December 2016 69 Supplement 1:S132-S132

Selumetinib-based therapy in uveal melanoma patient-derived xenografts.

Autor: Decaudin D; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University Paris, Paris, France.; Department of Medical Oncology, Institut Curie, Paris, France., El Botty R; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University Paris, Paris, France., Diallo B; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University Paris, Paris, France., Massonnet G; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University Paris, Paris, France., Fleury J; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University Paris, Paris, France., Naguez A; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University Paris, Paris, France., Raymondie C; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University Paris, Paris, France., Davies E; IMED Oncology, AstraZeneca, Cambridge, UK., Smith A; IMED Oncology, AstraZeneca, Cambridge, UK., Wilson J; IMED Oncology, AstraZeneca, Cambridge, UK., Howes C; IMED Oncology, AstraZeneca, Cambridge, UK., Smith PD; IMED Oncology, AstraZeneca, Cambridge, UK., Cassoux N; Department of Oncological Ophthalmology, Institut Curie, Paris, France., Piperno-Neumann S; Department of Medical Oncology, Institut Curie, Paris, France., Roman-Roman S; Department of Translational Research, Institut Curie, PSL University Paris, Paris, France., Némati F; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University Paris, Paris, France.

Publikováno v: Oncotarget [Oncotarget] 2018 Apr 24; Vol. 9 (31), pp. 21674-21686. Date of Electronic Publication: 2018 Apr 24 (Print Publication: 2018).

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.

Autor: Carita G; Laboratory of Preclinical Investigation, Department of Translational Research, PSL University, Institut Curie, Paris, France., Frisch-Dit-Leitz E; Department of Translational Research, Institut Curie, PSL University, Paris, France., Dahmani A; Laboratory of Preclinical Investigation, Department of Translational Research, PSL University, Institut Curie, Paris, France., Raymondie C; Laboratory of Preclinical Investigation, Department of Translational Research, PSL University, Institut Curie, Paris, France., Cassoux N; Department of Ophthalmological Oncology, Institut Curie, Paris, France., Piperno-Neumann S; Department of Medical Oncology, Institut Curie, Paris, France., Némati F; Laboratory of Preclinical Investigation, Department of Translational Research, PSL University, Institut Curie, Paris, France., Laurent C; Residual Tumor & Response to Treatment Laboratory, Department of Translational Research, Institut Curie, PSL University, Paris, Paris, France., De Koning L; RPPA Platform, Department of Translational Research, Institut Curie, PSL University, Paris, France., Halilovic E; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Jeay S; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Wylie A; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Emery C; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Roman-Roman S; Department of Translational Research, Institut Curie, PSL University, Paris, France., Schoumacher M; Department of Translational Research, Institut Curie, PSL University, Paris, France., Decaudin D; Laboratory of Preclinical Investigation, Department of Translational Research, PSL University, Institut Curie, Paris, France.; Department of Medical Oncology, Institut Curie, Paris, France.

Publikováno v: Oncotarget [Oncotarget] 2016 Jun 07; Vol. 7 (23), pp. 33542-56.

Predicting anticancer synergistic drug combinations based on multi-task learning.

Autor: Chen, Danyi¹ (AUTHOR), Wang, Xiaowen¹ (AUTHOR), Zhu, Hongming¹ (AUTHOR), Jiang, Yizhi¹ (AUTHOR), Li, Yulong¹ (AUTHOR), Liu, Qi² (AUTHOR) qiliu@tongji.edu.cn, Liu, Qin¹ (AUTHOR) qin.liu@tongji.edu.cn

Publikováno v: BMC Bioinformatics. 11/27/2023, Vol. 24 Issue 1, p1-19. 19p.

Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth.

Autor: Han, Anna^1,2 (AUTHOR) annahan8659@jbnu.ac.kr, Mukha, Dzmitry³ (AUTHOR) dmukha@wistar.org, Chua, Vivian¹ (AUTHOR) vivian.chua@jefferson.edu, Purwin, Timothy J.¹ (AUTHOR) timothy.purwin@jefferson.edu, Tiago, Manoela¹ (AUTHOR) manoela.tiagodossantos@jefferson.edu, Modasia, Bhavik¹ (AUTHOR) usman.baqai@students.jefferson.edu, Baqai, Usman¹ (AUTHOR) emily.hunter@students.jefferson.edu, Aumiller, Jenna L.⁴ (AUTHOR) jenna.aumiller@students.jefferson.edu, Bechtel, Nelisa¹ (AUTHOR), Hunter, Emily¹ (AUTHOR), Danielson, Meggie⁵ (AUTHOR) meggie.danielson@jefferson.edu, Terai, Mizue⁵ (AUTHOR) mizue.terai@jefferson.edu, Wedegaertner, Philip B.⁴ (AUTHOR) philip.wedegaertner@jefferson.edu, Sato, Takami⁵ (AUTHOR) takami.sato@jefferson.edu, Landreville, Solange⁶ (AUTHOR) solange.landreville@fmed.ulaval.ca, Davies, Michael A.⁷ (AUTHOR) mdavies@mdanderson.org, Kurtenbach, Stefan^8,9,10 (AUTHOR) stefan.kurtenbach@med.miami.edu, Harbour, J. William^8,9,10,11 (AUTHOR) william.harbour@utsouthwestern.edu, Schug, Zachary T.³ (AUTHOR) zschug@wistar.org, Aplin, Andrew E.^1,12 (AUTHOR) andrew.aplin@jefferson.edu

Publikováno v: Cancers. Jul2023, Vol. 15 Issue 13, p3451. 23p.